Insider Selling: 4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells 2,407 Shares of Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider Scott Bizily sold 2,407 shares of 4D Molecular Therapeutics stock in a transaction on Tuesday, September 23rd. The shares were sold at an average price of $8.00, for a total value of $19,256.00. Following the transaction, the insider owned 7,596 shares in the company, valued at approximately $60,768. This trade represents a 24.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

4D Molecular Therapeutics Stock Performance

Shares of FDMT stock opened at $8.35 on Tuesday. 4D Molecular Therapeutics, Inc. has a 1 year low of $2.23 and a 1 year high of $11.13. The stock has a market cap of $389.95 million, a PE ratio of -2.37 and a beta of 2.85. The business’s fifty day moving average is $6.41 and its 200-day moving average is $4.61.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings results on Monday, August 11th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.10). 4D Molecular Therapeutics had a negative net margin of 594,375.81% and a negative return on equity of 40.15%. The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.52 million. Equities research analysts predict that 4D Molecular Therapeutics, Inc. will post -2.84 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on FDMT shares. Chardan Capital reiterated a “buy” rating and set a $25.00 price target on shares of 4D Molecular Therapeutics in a research report on Tuesday, August 12th. Roth Capital reduced their price objective on 4D Molecular Therapeutics from $44.00 to $38.00 and set a “buy” rating for the company in a research note on Tuesday, August 12th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Saturday, September 13th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $30.40.

Institutional Trading of 4D Molecular Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. Rangeley Capital LLC acquired a new stake in shares of 4D Molecular Therapeutics in the second quarter worth $48,000. Man Group plc boosted its position in shares of 4D Molecular Therapeutics by 159.7% in the second quarter. Man Group plc now owns 134,932 shares of the company’s stock worth $501,000 after buying an additional 82,980 shares during the period. BNP Paribas Financial Markets boosted its position in shares of 4D Molecular Therapeutics by 128.5% in the second quarter. BNP Paribas Financial Markets now owns 63,914 shares of the company’s stock worth $237,000 after buying an additional 35,948 shares during the period. Bridgeway Capital Management LLC boosted its position in shares of 4D Molecular Therapeutics by 100.3% in the second quarter. Bridgeway Capital Management LLC now owns 25,000 shares of the company’s stock worth $93,000 after buying an additional 12,516 shares during the period. Finally, BVF Inc. IL boosted its position in shares of 4D Molecular Therapeutics by 1.5% in the second quarter. BVF Inc. IL now owns 4,629,289 shares of the company’s stock worth $17,175,000 after buying an additional 68,000 shares during the period. Institutional investors and hedge funds own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.